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During a period of 18months beginning in January 1982,
a total of 6S patients were referred to the Miami Heart
Institute for evaluation of either aborted out of hospital
sudden death, ventricular tachycardia resistant to stan-
dard clinically directed antiarrhythmic medication pro-
grams or high grade ventricular arrhythmia (Lown class
2: IV B) with or without syncope. After complete eval-
uation including cardiac catheterization in all but 1 pa-
tient, 17 patients were identified in whom no obvious
cardiac disease could be found. Twelve of the 17 under-
went right ventricular endomyocardial biopsy. Sixof the
12 biopsies demonstrated clinically unsuspected lym-
phocytic myocarditis (Group A). Findings in three of the
remaining six biopsies were consistent with an early car-
diomyopathyand in three werecompletely normal (Group
B). Retrospective review of the clinical, laboratory, elec-
trophysiologic, hemodynamicand angiographicdata failed
to identify a marker that reliably separated Group A
from Group B patients.
In addition to antiarrhythmic therapy guided by lab-
The treatment of patients with recurrent ventricular tachy-
cardia is a common and perplexing problem. With the advent
of electrophysiologic testing, a formal approach to such
patients has developed that, with ambulatory electrocardi-
ography, permits accurate characterization of the arrhythmia
and its hemodynamic consequences (1-3). The efficacy of
specific antiarrhythmic drug programs can often be quickly
assessed in the laboratory and these data, although not per-
fectly predictive, seem to correlate well with the long-term
course of the patients (4-6). Many well designed studies
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oratory electrophysiologic study, all Group A patients
were treated with prednisone and azathioprine. After 6
months of immunosuppression, all patients with myo-
carditis were reevaluated in the hospital without antiar-
rhythmic medication. Ventricular tachycardia/fibrilla-
tion could not be provoked in the laboratory during
repeat electrophysiologic testing in five of the six pa-
tients. Repeat myocardial biopsy after all immunosup-
pressive therapy had been discontinued revealed absence
of inflammation associated with varying degrees of re-
sidual interstitial fibrosis. There were no deaths.
It was concluded that a patient with an otherwise
clinically silent lymphocytic myocarditis can present with
potentially life-threatening ventricular arrhythmias. The
diagnosis can only be made with certainty by endomyo-
cardial biopsy. Our preliminary uncontrolled observa-
tions suggest that such patients may have a beneficial
electrophysiologic and histologic response to a course of
immunosuppressive therapy.
(7-12) have reported the clinical and electrophysiologic
characteristics of large groups of patients with ventricular
tachycardia. In almost all these studies, a small group of
patients is included in whom no obvious cardiac disease can
be found to explain these potentially life-threatening
arrhythmias.
To gain additional understanding of this problem, we
reviewed our experience with a group of consecutive pa-
tients referred for study because of significant ventricular
arrhythmias. After a complete cardiac evaluation including
electrophysiologic testing and cardiac catheterization, those
patients with no obvious cardiac disease were further studied
with serial right ventricular endomyocardial biopsies. Fifty
percent of these patients undergoing biopsy had a lympho-
cytic myocarditis that was unsuspected and otherwise clin-
ically silent.
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Methods
Study patients. The records of the clinical electrophys-
iologic laboratory of the Miami Heart Institute were re-
viewed for the 18 month period beginning in January 1982,
The hospital records of all patients who were referred for
study primarily because of 1) aborted out of hospital sudden
death, 2) ventricular tachycardia resistant to standard clin-
ically directed arrhythmia medication programs, and 3) high
grade ventricular arrhythmia (Lown class 2: IV B) with or
without syncope were examined.
The results of clinical examination and noninvasive stud-
ies (chest roentgenography, rest and stress electrocardiog-
raph). 24 hour ambulatory electrocardiography and echo-
cardiography) as well as diagnostic cardiac catheterization
were reviewed. All patients in whom a definite cause of the
ventricular arrhythmias could not be established were se-
lected for further study,
During the 18 month study period, a total of 65 patients
were referred for evaluation. Cardiac catheterization was
performed in 64 of the patients before formal electrophys-
iologic study. The ventricular arrhythmias were related to
coronary artery disease in 40 patients, valvular heart disease
in 4, primary myocardial disease in 3 and congenital heart
disease (status post-tetralogy of Fallot repair) in 1 patient.
None of the 65 patients had echocardiographic or angio-
graphic evidence of arrhythmogenic right ventricular dys-
plasia (13).
In 17 patients, the cause of the ventricular arrhythmias
remained unclear after noninvasive evaluation and cardiac
catheterization. Twelve of the 17 patients underwent right
ventricular biopsy. The five patients who did not undergo
biopsy were seen before we became aware of the possible
association between unexplained ventricular arrhythmias and
lymphocytic myocarditis.
Myocardial biopsy. During the same period, we be-
came increasingly aware that right ventricular endomycar-
dial hiopsy in patients with otherwise unexplained ventric-
ular arrhythmia would occasionally reveal histologic evidence
of lymphocytic myocarditis (14). By July 1982, we began
to recommend that all such patients undergo biopsy. The
biopsy material was obtained using the percutaneous trans-
venous techniques described by Mason (15). Between three
and six pieces of myocardium were obtained from each
patient, usually from different locations within the right
ventricle in an attempt to avoid false negative biopsies and
to reduce, the sampling error. The specimens were fixed in
2.5% phosphate-buffered (pH 7,35) glutaraldehyde at room
temperature. The fixed biopsy material was then processed
in the manner described by Fenoglio (16), The slides were
examined independently by two cardiac pathologists who
were asked to confirm or exclude the presence of lympho-
cync myocarditis but who had no knowledge of the clinical
problem.
The diagnosis of lymphocytic myocarditis was made if
the following histologic criteria, suggested by Margaret
Billingham, MD (personal communication), were noted: I)
diffuse or focal interstitial mononuclear infiltration 2) no or
minimal interstitial fibrosis, 3) absence of myofiber hyper-
trophy, and 4) absence of bizarre-shaped myocyte nuclei.
The criteria recently suggested by Edwards et al. (14) were
also met.
Electrophysiologic testing. All electrophysiologic test-
ing was performed with the patient in the fasting nonsedated
state. All antiarrhythmic medication was withdrawn at least
72 hours before the study. Multiple bipolar electrode cath-
eters were inserted for intracardiac stimulation and record-
ing, The data were recorded on a Hewlett-Packard 3968A
eight channel tape recorder and printed on a Mingograf 82
ink jet recorder. Three orthogonal surface electrocardio-
graphic leads were recorded simultaneously with intracar-
diac electrograms at a paper speed of 100 mm/s. Rectangular
stimuli of 1 ms duration were delivered at twice diastolic
threshold by a custom-designed computer-assisted Cordis
electrophysiologic stimulator (Cordis Corporation, using
software designed by Edward Smith, PhD, of Cordis Cor-
poration),
Sinus node function and atrioventricular conduction eval-
uation were performed using standard electrophysiologic
techniques (17,18), Ventricular stimulation with up to six
programmed impulses was carried out using a standardized,
progressive three part stimulation protocol (19). We have
shown that in our patient group, the sensitivity, specificity
and predictive accuracy of the stimulation protocol utilized
are 97,85 and 92%, respectively (19). Induction of 10 or
more consecutive ventricular complexes was considered a
positive response for the purposes of this study.
After the induction of reproducible ventricular tachy-
cardia/fibrillation in the laboratory using the protocol just
described, patients were given lidocaine, procainamide,
propranolol and diphenylhydentoin intravenously on se-
quential days, After each drug infusion, the entire stimu-
lation protocol was repeated to determine whether that drug
prevented the reinduction of the tachyarrhythmia. Blood
levels were monitored at the time of testing if appropriate.
If all standard antiarrhythmic medication failed to prevent
the reinduction of ventricular tachycardia, the procedure was
terminated and the patient started on treatment with oral
amiodarone. In all patients, the efficacy of the antiar-
rhythmic program selected was reconfirmed by multiple 24
hour electrocardiographic recordings and follow-up exercise
treadmill testing.
In addition, patients whose endomyocardial biopsy re-
vealed lymphocytic myocarditis were started on the program
of immunosuppressive therapy with prednisone and aza-
thioprine suggested by Mason and Billingham (20), Briefly,
therapy was divided into three phases: initial therapy, dose
tapering and maintenance treatment.
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Table 1. Clinical Data
*Probablhty value not sigmficant.
CK = serum creanne kinase; CK-M = myocardial creatine kinase
Isoenzyme; CXR = chest X-ray film; ECG = electrocardiogram: echo
= echocardiogram.
Group A Group B
(6 patients With (6 panents Without
myocarditis) myocardius)
Age (yr] 28 to 62 17 to 71
(mean 47 7)* (mean 44.5)*
Male 5 3
Anginal chest pam 0 0
Atypical chest pain 5 4
Fever 0 0
Congestive heart failure I I
Palpitation 6 6
Syncope 2 2
Cardiac arrest 2 2
Viral illness 4 I
Duration of Illness (rno) I to 12 I to 120
(mean 5.4)* (mean 26.8)*
2 of 6
I of 5
3 of 6
oof 6
oof 5
oof 6
o of 6
oof 2
oof I
oof I
Group B
(6 patients WIthout
myocarditis)
oof 6
oof 4
I of 6
I of 6
oof 6
2 of 6
2 of 6
oof 0
oof 2
oof 2
Group A
(6 patients with
myocarditis)
Cardiac enlargement (CXR)
Cardiac enlargement (echo)
ST-T wave changes (ECG)
Leukocytosis
Abnormal sedimentation rate
Elevated CK
Elevated CK-MB
Abnormal gallium scan
Abnormal VIral titers
Abnormal toxoplasmosis titers
Table 2. Laboratory Data
shock had elevations of both serum total creatine kinase and
its myocardial isoenzyme. In one of these patients, the initial
white blood count was elevated but promptly returned to
normal after hospitalization. The remaining four patients in
Group A who did not undergo electrical defibrillation just
before hospital admission had a normal white blood count,
erythrocyte sedimentation rate and cardiac enzyme profile.
In only two of the six patients with myocarditis was serum
drawn in the acute and convalescent stages to obtain evi-
dence of recent toxoplasmosis or viral illness; in both pa-
tients, the titers were normal. No patient in the myocarditis
group (Group A) had a gallium myocardial scan performed.
All six patients in the myocarditis group had normal anti-
nuclear antibody titers. No clinical marker studied reliably
predicted the presence of myocarditis histologically.
Catheterization data (Table 3). With the exception of
one patient in Group B, all patients underwent complete
Immunosuppressive therapy. Initially, prednisone. I
mg/kg per day. and azathioprine. 1.25 mg/kg per day, were
administered. After I week, the dose of prednisone was
slowly decreased over 3 to 6 weeks until a maintenance
dose of 0.3 mg/kg per day was reached. The dose of aza-
thioprine was left unchanged unless the patient developed
leukopenia. Maintenance therapy was then continued for at
least 6 months. Repeat endomyocardial biopsy was per-
formed during maintenance therapy to be certain that the
lower doses of immunosuppression effectively eliminated
the inflammation. Biopsy was repeated once again after all
immunosuppressive therapy was discontinued to determine
the extent of residual inflammation and fibrosis.
Follow-up. After the course of immunosuppressive ther-
apy, all patients were readmitted for repeat electrophysio-
logic study. Before the study, all antiarrhythmic medication
was withheld during constant electrocardiographic moni-
toring. The protocol and stimulation sequence of the follow-
up electrophysiologic study were the same as that of the
pretreatment one.
Statistical methods. Student's t test was used to com-
pare the ages, duration of illness, left ventricular ejection
fraction and left ventricular filling pressure of the study
patients.
Results
Myocardial biopsy. Six of the 12 patients undergoing
biopsy had the diagnosis of lymphocytic myocarditis con-
firmed histologically (Group A). The remaining six had no
evidence of myocarditis (Group B). In three of these latter
six patients, myocellular hypertrophy associated with in-
terstitial and perivascular fibrosis was noted. Although these
findings were not specific, they were thought to be consistent
with cardiomyopathy (21). The remaining three biopsies
were considered histologically normal. No patient in either
group had an eosinophilic infiltrate noted on biopsy, as has
been reported with drug-induced hypersensitivity myocar-
ditis (22).
Clinical data (Table 1). No patient in either Group A
or B was febrile. The duration of illness in the patients with
myocarditis tended to be less than in those whose biopsies
showed no evidence of inflammation (5.4 versus 26.8 months),
but this difference was not statistically significant. Five of
the six patients with myocarditis reported an atypical non-
anginal-like chest pain. Four of the six without myocarditis
reported similar pain. No aspect of the historical data re-
liably predicted which patients would have lymphocytic my-
ocarditis on biopsy.
Laboratory data (Table 2). No patient in either Group
A or B had an abnormally elevated erythrocyte sedimen-
tation rate. Two patients with myocarditis (Group A) who
were successfully resuscitated using direct current counter-
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EeG = electrocardiogram; EPS = electrophysiologic study: PYCs =
premature ventricular complexes: YF = ventricular fibrillation. YT =
ventn cular tachycardia.
cardiac catheterization with coronary angiography. The one
patient not catheterized was a 17 year old youth whose
complete noninvasive evaluation was normal and who was
presumed not to have coronary atherosclerosis. By study
design all catheterized patients had normal coronary arteries.
There was no significant difference between the myocarditis
group (Group A) and nonmyocarditis group (Group B) in
left ventricular filling pressures and global ejection fraction.
Four of the six patients with myocarditis had a normal ejec-
tion traction (2: 60%). compared with three of the six in
the nonmyocarditis group. There were no hemodynamic or
angiographic markers that distinguished the myocarditis from
the nonmyocarditis group.
Electrophysiologic testing (Table 4). No complications
resulted from the study protocol. All patients in both Group
A and B had high grade ventricular arrhythmia (Lown clas-
sificanon 2: IV B). Three patients in each group had non-
sustamed runs of ventricular tachycardia reported on a 24
hour ambulatory electrocardiogram. Five of the six patients
"p > NS: LY = left ventricular.
Table 3. Catheterization Data with biopsy-proven myocarditis (Group A) underwent for-
mal intracardiac electrophysiologic stimulation and testing.
One patient refused study. Among the five patients studied,
ventricular fibrillation was induced in two, and nonsustained
ventricular tachycardia was induced in two. In the remaining
patient, neither ventricular fibrillation nor ventricular tachy-
cardia could be induced in the laboratory with the protocol
employed.
One of the six patients without myocarditis (Group B)
refused study. Ventricular tachycardia could not be initiated
in three of the remaining five patients in this group; ven-
tricular fibrillation was induced in the other two. No elec-
trophysiologic variable studied reliably distinguished the
myocarditis from the nonmyocarditis group.
Antiarrhythmic therapy. Five of the six patients with
myocarditis were treated with antiarrhythmic agents; these
drugs were not given to the patient in whom ventricular
tachycardia or fibrillation could not be induced in the lab-
oratory. In two of the five treated patients, standard antiar-
rhythmic agents (procainamide in one and propranolol and
diphenylhydantoin in the other) successfully protected the
patients from catheter reinduction of ventricular tachycardia
or fibrillation. Two patients with myocarditis (Group A)
whose arrhythmias continued to be inducible in spite of
conventional antiarrhythmic medications were given oral
amiodarone. The one patient in the myocarditis group who
refused electrophysiologic study was started empirically on
oral procainamide.
Of the six patients in the nonmyocarditis group, three
were adequately protected with a standard antiarrhythmic
agent (procainamide) and two were given amiodarone. The
patient in this group who refused electrophysiologic study
was treated empirically with procainamide.
Immunosuppressive therapy. All six of the patients
with myocarditis were given prednisone and azathioprine in
addition to their other medications. Patients without myo-
carditis did not receive immunosuppressive therapy.
All patients in the myocarditis group became clinically
"cushingoid" with the doses of prednisone employed.
However. only one patient needed a reduction in the dose
of prednisone because of the development of diabetes mel-
litus requiring insulin therapy and the development of a
reversible steroid-induced proximal skeletal myopathy. No
patient developed leukopenia requiring a reduction in the
dose of azathioprine. No patient developed opportunistic
infection. All six patients in this group underwent repeat
myocardial biopsy when maintenance immunosuppressive
therapy was reached in 6 to 8 weeks, and all six demon-
strated histologic evidence of either a marked reduction or
absence of inflammation, usually associated with an increase
in the amount of interstitial fibrosis (Fig. 1).
Follow-up evaluation. After 6 months of immunosup-
pressive therapy. the patients in the myocarditis group were
reevaluated in the hospital after cessation of all antiar-
3 of 3
2 of 3
6 of 6
3 of 6
5 of 6
3 of 5
oof 5
2 of 5
6 of 6
4 of 6
2 of 6
oof 6
5 of 6
5 of 5
6 to 11
(mean 9)*
40 to 72
(mean 57.9)*
3 of 6
Group B
(6 patients Without
myocarditts)
Group B
(6 panents without
myocarditis)
6 of 6
6 of 6
10 to 20
(mean 12)*
44 to 69
(mean 59 3)*
4 of 6
6 of 6
3 of 6
5 of 6
I of 5
2 of 5
2 of 5
5 of 6
3 of 5
2 of 5
6 of 6
4 of 5
oof 5
Group A
(6 patients with
myocarditis)
Stress ECG
PVC,
YT
24 hour ECG
Pyes
YT
EPS performed
YT not inducible
YT mducible
YF inducible
Antiarrhythmic therapy
Standard
Armodarone
Immunosuppressive
Table 4. Electrophysiologic Data
Group A
(6 patients with
myocarditis)
Normal ~Jection fraction (2"600/c)
Ejecnon fraction (%)
Catheterization performed
Normal coronary arteries
LY filling pressure (rnm Hg)
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rhythmic medication. Ventricular tachycardia or fibrillation
could not be provoked in the laboratory during repeat elec-
trophys iologic testing in four of the five patients (Fig. 2).
Only the patient in whom the development of side effects
prompted an immunosuppressive dose reduction continued
to have catheter-induced ventricular tachycardia after ther-
apy . In the remaining five patients who no longer required
immunosuppression, repeat myocardial biopsy revealed ab-
sence of inflammation with varying degrees of residual in-
terstitial fibrosis.
Discussion
Most large reported series (7- 12) of patients with ven-
tricular tachyarrhythmias contain some individuals in whom
no cause for the arrhythmia can be determined despite a
complete cardiac evaluation. The reported prevalence of
such individuals is quite variable. ranging between 2 and
36% depending on patient selection. In the present series
of 65 patients referred for evaluation of ventricular tach-
yarrhythmia, no definite cause could be determined in 17
of the patients (26%). Of the 12 patients who underwent
myocard ial biopsy, 6 had definite evidence of lymphocyt ic
Figure 1. Right ventricular endomyocardial biopsy specimens from
a patient with biopsy-proven myocarditis . A. Myocardial biopsy
specimen before immunosuppressive therapy . A prominent mono-
nuclear infiltrate is noted in the interstitium. B, Biopsy specimen
after a 6 month course of predn isone and azathioprine. The inter-
stitial infiltrate is gone. An increase in connective tissue is evident
between myocytes.
myocarditis that was otherwise clinically silent. Results of
the biopsies in the remaining six patients were either com-
pletely normal or consistent with an early cardiom yopathy
(21). After a course of immunosuppressive therapy, not only
did the histologic evidence of myocarditi s resolve, but also
the ventricular tachycardia that was inducible with pro-
grammed extrastimulation could no longer be induced with
the patient taking no antiarrhythmic medication .
Lymphocytic myocarditis. The clinical syndrome of
acute myocarditis is well defined (23). However, the concept
of a smoldering subacute or chronic myocarditi s is one that
is currently evolving based on the data that are now being
accumulated from endoymocardial biopsy material obta ined
from patients with congestive heart failure of unknown cause.
Mason et al. (24) reported histologic evidence of lympho-
JACC V'" 4. No 4
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Figure 2. Electrophysiologic testing in the same
patient as in Figure I. Panel A. Results of testing
without antiarrhythmic medication before immu-
nosuppressive therapy. During ventricular pacing
(St) at a cycle length (Cl.) of 500 rns. two pro-
gramrned ventricular stimuli (S2 and S3) induce a
monomorphic ventricular tachycardia (VT) with a
cycle length of 270 ms that was similar in rate and
configuration to the clinical tachycardia. Panel B,
Repeat testing in the same patient without antiar-
rhythn IIC medication after a6 month course ofpred-
nisone .md azathioprine. The more aggressive pro-
tocol l 'l six programmed extrastimuli (S2,S" S4,S5,
So,S?) tails to initiate any repetitiveresponse. HBE
= His bundle electrogram;HRA = high rightatrial
electrogram; NSR = normal sinus rhythm.
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cytic myocarditis in patients thought clinically to have a
dilated congestive cardiomyopathy. The inflammatory pro-
cess in these patients was clinically unsuspected and was
only detected by endomyocardial biopsy. A small number
of these patients responded to immunosuppressive therapy
with hemodynamic improvement that was parallelled by
histologic resolution of the infiltrate. These findings have
been confirmed by others (25) . More recently Fenoglio et
al. C6) devised histologic classifications that seemed to
predict their patients' clinical course and response to im-
munosuppressive therapy.
The pathog enesis of this illness is speculative . However.
an increasing amount of experimental (27.28) and clinical
(29.30) data would suggest that patients are infected with
particular strains of myocardiotrophic viruses. After a rel-
atively short period of time, the viruses are cleared from
the myocardium. However. during the periodof infectivity,
the viruses alter certain myocyte proteins to produce " neo
antigens" (29,31,32). In certain patients with either inher-
ited or acquired abnormalities in suppressor T cell function,
the immunologic process mediated by the cytotoxic T lym-
phocyte is directed against the " neo antigen" producing a
continuing low grade inflammatory response that may ul-
timately culminate in an "idiopathic" congestive cardio-
myopathy (29- 35).
Unexplained ventricular arrhythmias. The concept that
potentially life-threatening ventricular arrhythmias can be
related to otherwise clinically silent myocarditis is intrigu-
ing. Van Hoogenhuyze et al. (36) reported on IS patients
with ventricular tachycardia in whom an underlyingcardiac
abnormality could not be demonstrated. Four of the 15 pa-
tients had endomycardial biopses consistent with "chronic
myocarditis. " No comment was made in this preliminary
report concerningtreatmentor follow-up. Reeder et al. (37)
reported preliminary data on 17 patients with unexplained
life-threatening ventricular arrhythmias, 5 of whom had
myocardial biopsy findings of "myocarditis with lympho-
cytic infiltration and interstitial edema." Four patients re-
ceived steroid therapy. Three showed resolution of the in-
flammation on serial biopsy. However, in two of these three
patients, persistent arrhythmia required specific antiar-
rhythmic therapy. The results of our current study support
these preliminary data. In addition, careful review of the
clinical, electrocardiographic, laboratory, hemodynamic an-
giographic and formalelectrophysiologic data of the current
study suggests that the ventricular arrhythmia may be the
only manifestationofanotherwise clinicallysilentmyocarditis.
Recently, Strain et a1. (38) reported the results of right
ventricular endomyocardial biopsy in patients with spon-
taneous ventricular tachycardia but without apparent heart
disease. Nine of their 18 patients had biopsy findings con-
sistent with an early cardiomyopathy; 2 had diffuse abnor-
malities of the intramyocardial arteries, 2 had arrhythmo-
genic right ventricular dysplasia. 2 were normal and 3 had
" subacute inflammatory myocarditis" . The patients with
myocarditis were not given immunosuppressivetherapyand
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the investigators concluded that the . 'performance of right
ventricular biopsies in this group of patients should be con-
sidered a research procedure." However, in our study. the
histologic and clinical response of our patients to immu-
nosuppressive therapy was both interesting and gratifying.
Before immunosuppressive therapy. all had either ventric-
ular tachycardia or had been resuscitated from cardiac arrest
secondary to ventricular fibrillation. Four of the five patients
studied had their clinical arrhythmia induced in the electro-
physiology laboratory. After immunosuppressive therapy,
clinical arrhythmias were abolished in five patients and re-
mained unchanged in one. In four of the five patients re-
studied in the electrophysiology laboratory while they were
not taking antiarrhythmic and antiinflammatory medication,
ventricular tachyarrhythmias could not be induced using the
same or a more aggressive stimulation protocol. This clinical
and electrophysiologic improvement was associated with a
concomitant resolution of the inflammatory infiltrate.
Cautionary points. Several cautionary points are wor-
thy of special emphasis. The response of our patients with
myocarditis to immunosuppressive therapy is uncontrolled.
The natural history of this entity treated with aggressive
antiarrhythmic therapy guided by electrophysiologic study
without immunosuppression is unknown. It is entirely pos-
sible that both the inflammatory infiltrate and the arrhyth-
mias would have resolved spontaneously without immu-
nosuppression. However, it is equally possible that these
patients might have eventually developed the typical picture
of an "idiopathic" dilated congestive cardiomyopathy if
they had not received immunosuppressive therapy. It is en-
tirely possible that those patients who initially present with
a dilated heart and congestive heart failure go through a
stage in their illness before the heart dilates, in which they
are at increased risk of a serious ventricular arrhythmia. The
disease may be detected at this early stage only if it manifests
itself by a recognized clinical arrhythmia. Finally, it should
be emphasized that the natural history of our" successfully"
treated patients is now unknown. They may still ultimately
develop a cardiomyopathic clinical syndrome despite res-
olution of the infiltrate and remission of the arrhythmias.
The answers to these and several other important questions
require a carefully designed and controlled clinical trial with
long-term clinical, electrophysiologic and histologic follow-
up.
Conclusion. We have shown that clinically unsuspected
myocarditis can present in the absence of cardiomegaly and
congestive heart failure as otherwise unexplained, poten-
tially life-threatening ventricular arrhythmias. None of the
clinical, electrocardiographic, laboratory, hemodynamic,
angiographic or electrophysiologic markers studied reliably
predicted which patients had myocarditis and which did not.
Because the diagnosis would have been missed if the biopsy
had not been performed, we now recommend that all such
patients undergo the procedure. If the biopsy reveals an
active inflammatory infiltrate on the basis of the data now
available, a trial of prednisone and azathioprine therapy
should be started. Serial biopsies should be performed dur-
ing therapy to assess its efficacy and again after therapy to
assess the degree of residual fibrosis. We believe that an-
tiarrhythmic therapy should be guided by electrophysiologic
testing to be certain that adequate arrhythmia control is
achieved during the course of immunosuppression. A fol-
low-up electrophysiologic study should be performed with
the patient not taking antiarrhythmic agents after immu-
nosuppressive therapy to determine whether continued ar-
rhythmia suppression is necessary.
We thank Margaret Billingham. MD for reviewing the endomyocardial
biopsies, MInor Duggan. MD for reviewing the manuscript, John Rothrock
for preparing the illustrations and Klara $oos for typing the manuscript.
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